Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Chrysalyne D. Schmults, Rachel Blitzblau, Sumaira Z. Aasi, Murad Alam, Arya Amini, Kristin Bibee, Jeremy S. Bordeaux, Pei-Ling Chen, Carlo M. Contreras, Dominick J. DiMaio, Jessica M. Donigan, Jeffrey M. Farma, Karthik Ghosh, Kelly L. Harms, Alan L. Ho, John N. Lukens, Lawrence A. Mark, Theresa Medina, Kishwer S. Nehal, Paul Nghiem, Kelly Olino, Soohyung Park, Tejesh Patel, Igor Puzanov, Jason T. Rich, Aleksandar Sekulić, Ashok R. Shaha, Divya Srivastava, Valencia D. Thomas, Courtney M. Tomblinson, Puja Venkat, Yaohui Xu, Siegrid S. Yu, Mehran Yusuf, Beth McCullough, Sara Espinosa
Abstract
Basal cell carcinoma (BCC) is the most common form of skin cancer in the United States. Due to the high frequency, BCC occurrences are not typically recorded, and annual rates of incidence can only be estimated. Current estimated rates are 2 million Americans affected annually, and this continues to rise. Exposure to radiation, from either sunlight or previous medical therapy, is a key player in BCC development. BCC is not as aggressive as other skin cancers because it is less likely to metastasize. However, surgery and radiation are prevalent treatment options, therefore disfigurement and limitation of function are significant considerations. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline an updated risk stratification and treatment options available for BCC.